• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Johnson’s obsession isn’t new or particularly unique. Celebrities have used everything from bird poop to snake venom to fight Father Time. The oldest known facial cream was found in a 2,700-year-old nobleman’s tomb in northern China.

Today, the global anti-aging industry is worth an estimated $62.6 billion and is expanding at a brisk annual pace of 6.7%. Botox alone is worth over $6.1 billion, according to Fortune Business Insights.

Put simply, this is a lucrative market. And it’s expanding rapidly as the global population ages. If you want to get in on that action, here are some publicly listed stocks that can give you exposure to this trend.

Unity Biotech

Unity Biotechnology (UBX) is, perhaps, the only pure-play anti-aging stock of its size on the market right now.

The drug research and development company is focused exclusively on issues related to senescent cells — the cells that stop dividing as we get older. Unity is backed by tech heavyweights like Jeff Bezos and Peter Thiel, which is probably why it deserves a spot on your watch list too.

The stock is down about 90% from early-2021. It’s now worth just $53.9 million. As such, investors should be aware of the inherent risks of a small-cap biotech stock before diving in here.

Find a financial adviser in minutes

Are you confident in your retirement savings? Get advice on your investment portfolio from a certified professional through WiserAdvisor. It only takes 5 minutes to connect with an adviser who puts you first.

Get Started


Unlike the other stocks on this list, Cutera (CUTR) isn’t a risky biotech firm. Instead, it manufactures devices based on proven technology for the cosmetic industry. This includes laser systems for skin rejuvenation and pigment removal as well as body sculpting devices for lipolysis and fat removal.

The company delivered $253 million in revenue last year, 16% higher than 2021. However, the company did lose $3.90 per share in the first nine months of 2022. Perhaps steady growth could make it profitable eventually.

Crispr Therapeutics

The genetic information in every cell plays a key role in the body’s aging process. Now, scientists have discovered a way to use the CRISPR-Cas9–based gene editing technology to identify genes that could affect cellular senescence.

Gene therapy is a particularly promising way to fight aging, however these treatments are far from proven or mainstream yet. If successful, these treatments could unlock tremendous value for Crispr Therapeutics (CRSP).

The company has lost roughly three-quarters of its value since early-2021. However, it’s still worth $3.63 billion — which indicates how exciting this technology is. Investors could keep an eye on this gene editing pioneer.


Follow These Steps if you Want to Retire Early

Secure your financial future with a tailored plan to maximize investments, navigate taxes, and retire comfortably.

Zoe Financial is an online platform that can match you with a network of vetted fiduciary advisors who are evaluated based on their credentials, education, experience, and pricing. The best part? - there is no fee to find an advisor.

About the Author

Vishesh Raisinghani

Vishesh Raisinghani

Freelance Writer

Vishesh Raisinghani is a freelance contributor at MoneyWise. He has been writing about financial markets and economics since 2014 - having covered family offices, private equity, real estate, cryptocurrencies, and tech stocks over that period. His work has appeared in Seeking Alpha, Motley Fool Canada, Motley Fool UK, Mergers & Acquisitions, National Post, Financial Post, and Yahoo Canada.

What to Read Next


The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.